vs
Side-by-side financial comparison of AGENUS INC (AGEN) and Aligos Therapeutics, Inc. (ALGS). Click either name above to swap in a different company.
AGENUS INC is the larger business by last-quarter revenue ($34.2M vs $169.0K, roughly 202.4× Aligos Therapeutics, Inc.). AGENUS INC runs the higher net margin — -31.0% vs -11763.9%, a 11732.9% gap on every dollar of revenue. On growth, AGENUS INC posted the faster year-over-year revenue change (27.5% vs -72.1%). Over the past eight quarters, AGENUS INC's revenue compounded faster (10.5% CAGR vs -50.7%).
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
AGEN vs ALGS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $34.2M | $169.0K |
| Net Profit | $-10.6M | $-19.9M |
| Gross Margin | — | — |
| Operating Margin | 42.1% | -12907.7% |
| Net Margin | -31.0% | -11763.9% |
| Revenue YoY | 27.5% | -72.1% |
| Net Profit YoY | 77.3% | 75.8% |
| EPS (diluted) | $0.09 | $4.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.2M | $169.0K | ||
| Q3 25 | $30.2M | $741.0K | ||
| Q2 25 | $25.7M | $965.0K | ||
| Q1 25 | $24.1M | $311.0K | ||
| Q4 24 | $26.8M | $606.0K | ||
| Q3 24 | $25.1M | $1.3M | ||
| Q2 24 | $23.5M | $1.1M | ||
| Q1 24 | $28.0M | $694.0K |
| Q4 25 | $-10.6M | $-19.9M | ||
| Q3 25 | $63.9M | $-31.5M | ||
| Q2 25 | $-30.0M | $-15.9M | ||
| Q1 25 | $-26.4M | $43.1M | ||
| Q4 24 | $-46.8M | $-82.2M | ||
| Q3 24 | $-67.2M | $-19.3M | ||
| Q2 24 | $-54.8M | $5.1M | ||
| Q1 24 | $-63.5M | $-34.9M |
| Q4 25 | — | — | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | — | ||
| Q1 24 | 99.6% | — |
| Q4 25 | 42.1% | -12907.7% | ||
| Q3 25 | -15.0% | -3827.4% | ||
| Q2 25 | -65.0% | -1924.0% | ||
| Q1 25 | -55.3% | -6187.5% | ||
| Q4 24 | -96.5% | -3393.2% | ||
| Q3 24 | -125.5% | -1610.5% | ||
| Q2 24 | -128.4% | -2489.5% | ||
| Q1 24 | -117.4% | -3176.7% |
| Q4 25 | -31.0% | -11763.9% | ||
| Q3 25 | 211.4% | -4256.0% | ||
| Q2 25 | -116.8% | -1643.8% | ||
| Q1 25 | -109.6% | 13854.7% | ||
| Q4 24 | -174.4% | -13556.1% | ||
| Q3 24 | -267.7% | -1540.7% | ||
| Q2 24 | -233.1% | 477.0% | ||
| Q1 24 | -226.6% | -5023.5% |
| Q4 25 | $0.09 | $4.23 | ||
| Q3 25 | $1.94 | $-3.04 | ||
| Q2 25 | $-1.00 | $-1.53 | ||
| Q1 25 | $-1.03 | $-2.11 | ||
| Q4 24 | $-1.95 | $-13.10 | ||
| Q3 24 | $-3.08 | $-3.07 | ||
| Q2 24 | $-2.52 | $0.81 | ||
| Q1 24 | $-3.04 | $-5.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $77.8M |
| Total DebtLower is stronger | $44.7M | — |
| Stockholders' EquityBook value | $-271.1M | $53.5M |
| Total Assets | $226.8M | $88.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $77.8M | ||
| Q3 25 | $3.5M | $99.1M | ||
| Q2 25 | $9.5M | $122.9M | ||
| Q1 25 | $18.5M | $137.9M | ||
| Q4 24 | $40.4M | $56.9M | ||
| Q3 24 | $44.8M | $74.9M | ||
| Q2 24 | $93.7M | $94.5M | ||
| Q1 24 | $52.9M | $112.7M |
| Q4 25 | $44.7M | — | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $33.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-271.1M | $53.5M | ||
| Q3 25 | $-274.1M | $71.8M | ||
| Q2 25 | $-354.6M | $101.9M | ||
| Q1 25 | $-341.8M | $116.4M | ||
| Q4 24 | $-326.4M | $-29.0M | ||
| Q3 24 | $-292.3M | $50.1M | ||
| Q2 24 | $-241.3M | $67.2M | ||
| Q1 24 | $-201.4M | $59.8M |
| Q4 25 | $226.8M | $88.5M | ||
| Q3 25 | $233.9M | $109.8M | ||
| Q2 25 | $185.2M | $134.7M | ||
| Q1 25 | $200.2M | $150.7M | ||
| Q4 24 | $226.3M | $70.1M | ||
| Q3 24 | $238.5M | $88.4M | ||
| Q2 24 | $292.4M | $108.8M | ||
| Q1 24 | $256.6M | $127.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.6M | $-21.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.6M | $-21.7M | ||
| Q3 25 | $-14.7M | $-24.3M | ||
| Q2 25 | $-20.2M | $-15.5M | ||
| Q1 25 | $-25.6M | $-20.9M | ||
| Q4 24 | $-28.7M | $-18.4M | ||
| Q3 24 | $-53.3M | $-20.1M | ||
| Q2 24 | $-38.2M | $-19.5M | ||
| Q1 24 | $-38.2M | $-22.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | — | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.6M | — | ||
| Q1 24 | $-38.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | — | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | — | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | — | ||
| Q1 24 | -136.5% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
